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Abstract
Ovarian cancer is the most lethal gynecologic cancer mainly because of widespread peritoneal dissemination and
malignant ascites. Key to this is the capacity of tumor cells to escape suspension-induced apoptosis (anoikis), which
also underlies their resistance to chemotherapy. Here, we used a nonadherent cell culture model to investigate the
molecular mechanisms of apoptotic resistance of ovarian cancer cells that may mimic the chemoresistance found
in solid tumors. We found that ovarian cancer cells acquired a remarkable resistance to anoikis and apoptosis in-
duced by exposure to clinically relevant doses of two front-line chemotherapeutic drugs cisplatin and paclitaxel
when grown in three-dimensional than monolayer cultures. Inhibition of the hepatocyte growth factor (HGF) recep-
tor c-Met, which is frequently overexpressed in ovarian cancer, by a specific inhibitor or small interfering RNA
blocked the acquired anoikis resistance and restored chemosensitivity in three-dimensional not in two-dimensional
cultures. These effects were found to be dependent on both phosphatidylinositol 3-kinase (PI3K)/Akt and extra-
cellular signal–regulated kinase (ERK) 1/2 signaling pathways. Inhibitors of PI3K/Akt abrogated ERK1/2 activation
and its associated anoikis resistance in response to HGF, suggesting a signaling relay between these two pathways.
Furthermore, we identified a central role of Ras as a mechanism of this cross talk. Interestingly, Ras did not lie up-
stream of PI3K/Akt, whereas PI3K/Akt signaling to ERK1/2 involved Ras. These findings shed new light on the apop-
totic resistance mechanism of nonadherent ovarian cancer ascites cells and may have important clinical implications.
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Introduction
Ovarian cancer is the secondmost common type of female reproductive
tract malignancy, but it has the highest mortality of all the gynecologic
cancers [1]. This is largely because more than 70% of patients have their
conditions diagnosed at an advanced stage, with tumor spread beyond
the ovary and throughout the peritoneal cavity as ascites, which contain
free floating tumor cells that exist either as single cells or as multicellular
aggregates. Current therapies for advanced or metastatic ovarian cancer
are not effective owing to a high degree of inherent and acquired chemo-
resistance [2]. Thus, unraveling the molecular mechanisms of this
process is crucial for effectively targeting such cells therapeutically.
Several lines of evidence suggest that the c-Met oncogene encoded
tyrosine kinase receptor and its ligand hepatocyte growth factor (HGF)
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play an important role in the aggressive behavior of ovarian cancer.
First, c-Met is found to be expressed in approximately 70% of human
ovarian carcinomas and overexpressed in 30% of cases and cell lines
[3–5]. There was a significant inverse correlation between c-Met ex-
pression and a poor prognosis [6]. Second, high levels of HGF are
found in ovarian cancer ascitic fluids [7,8]. Third, we and others have
shown that HGF strongly promotes the growth and invasiveness of
ovarian cancer cells [7,9]. Fourth, blocking the effects of HGF by neu-
tralizing antibodies, the HGF antagonist, or knocking out c-Met ex-
pression by small interfering RNA (siRNA) was shown to inhibit
peritoneal dissemination and ascites formation of ovarian cancer cells
in vivo [6,10,11].
The ability to resist anoikis is a prerequisite for ovarian cancer cells
to survive in the ascites. However, the mechanism for activation of
anoikis resistance is not clear. Furthermore, ovarian cancer cells are
more resistant to drug-induced apoptosis when grown in three-
dimensional cultures than in monolayers [12,13]. Although sig-
nificant progress has been made in understanding the signaling
mechanisms of chemotherapeutic agents–induced apoptosis and re-
sistance, most studies are performed on monolayer cultures, which
are different from the clinical setting and presumably use different
molecular mechanisms. This may also help to explain why although
the in vitro findings are encouraging, they have not easily been trans-
lated into successful therapies [14].
In the present study, using a three-dimensional suspension culture,
we report for the first time that overexpression of c-Met enhanced
survival of ovarian cancer cells and increased resistance to the
front-line chemotherapeutic agents, cisplatin and paclitaxel, currently
used in the clinic. We also explored the molecular mechanisms by
which HGF inhibited apoptosis and that was dependent on phospha-
tidylinositol 3-kinase (PI3K)/Akt upstream of Ras to regulate extra-
cellular signal–regulated kinase (ERK)-1/2 signaling.
Materials and Methods
Cell Lines and Reagents
The OVCAR-3, CaOV-3, and SKOV-3 human ovarian carcinoma
cell lines (generously provided by Dr. Nelly Auersperg, Department of
Obstetrics andGynecology, University of British Columbia, Vancouver,
British Columbia, Canada) were grown in a 1:1mixture of medium199
(Invitrogen, Carlsbad, CA) and MDCB 105 (Sigma, St Louis, MO)
supplemented with 5% fetal bovine serum (Invitrogen). The growth
medium was supplemented with 50 μg/ml penicillin-streptomycin
(Invitrogen). Cell cultures were maintained at 37°C in a humidified
incubator with an atmosphere of 5% CO2.
Recombinant human HGF was purchased from R&D Systems, Inc
(Minneapolis, MN). PD98059, wortmannin, LY294002, rapamycin,
and K252a were from Calbiochem (San Diego, CA). Cisplatin and
paclitaxel were also obtained from Calbiochem. The pRS2-containing
human c-Met complementary DNA (cDNA) was kindly provided by
Dr. Vande Woude (Van Andel Research Institute, Grand Rapids, MI)
[15]. siRNA oligonucleotides targeting c-Met (5′-GUCAUAGGAA-
GAGGGCAUU-3′) [9], Akt (5′-UAAUGUGCCCGUCCUU-
GUC-3′), ERK1 (5′-UAAAGGUUAACAUCCGGUC-3′), ERK2
(5′-AAUAAGUCCAGAGCUUUGG-3′), and a nonspecific duplex
oligo (5′-GGCTACGTCCAGAGCGCA-3′) used as a negative con-
trol were purchased from Dharmacon (Lafayette, CO). Ras-specific
siRNA duplex (5′-AAGGACUCGGAUGACGUGC-3′) was ob-
tained from Santa Cruz Biotechnology (Santa Cruz, CA). A total of
10 nM of each siRNAwere transfected into CaOV-3 and SKOV-3 cells
using siLentfect (Bio-Rad, Hercules, CA) according to the manufac-
turer’s protocols. E17K Akt was generated by polymerase chain reaction
(PCR)–based site-directed mutagenesis using the forward primer 5′-
GGATCCATGAGCGACGTGGCTATTGTGAAGG-3′, and reverse
primer 5′-GGTCTTGATGTACTTCCCTCGTTTG-3′, and the
mutation incorporating oligonucleotide primers 5′-CAAACGAGGGA-
AGTACATCAAGACC-3′ and 5′-GAATTCTCAGGCCGTGCCGC-
TGGCCGAG-3″ (the mutated residue is underlined and restriction
sites of BamH1 and EcoR1 are in bold) and subcloned into pcDNA3.1.
The mutation was verified by sequencing. Transiently transfected cells
were grown for 24 hours and replated on agar-coated six-well plates for
expression and cell death analyses.
Induction of Anoikis
To prevent cell adhesion, six-well plates were coated by applying a
10-mg/ml solution of polyHEMA (polyhydroxyethylmethacrylate;
Sigma) dissolved in ethanol [16]. Three milliliters of polyHEMA
was added to each well and allowed to completely evaporate at 37°
C for at least 3 days. To induce anoikis, 2 × 105 cells were plated on
polyHEMA-coated dishes with or without HGF (10 ng/ml). Seventy-
two hours later, the cells were collected, and any cell aggregate was
dispersed by trypsin before apoptosis detection assays.
Apoptosis Assays
Apoptosis assays were carried out essentially as described [17].
Briefly, cells were washed once with PBS, and fixed with Carnoy’s
fixative (methanol/acetic acid, 3:1) for 10 minutes at room tempera-
ture. Ten microliters of this suspension was placed on a glass slide,
and Hoechst 33258 (50 ng/ml; Molecular Probes, Eugene, OR) was
added. The slides were subjected to fluorescence microscopic exami-
nation at an excitation wavelength of 350 nm. Apoptotic nuclei were
identified by the condensed chromatin or a total fragmented nuclear
bodies. At minimum, 200 cells were counted in five different fields,
and the percentage of apoptotic nuclei was determined.
Further characterization of apoptosis was performed using a commer-
cially available In Situ Cell Death Detection kit (Roche, Indianapolis,
IN) to find DNA breaks according to the manufacturer’s instructions.
Briefly, fixed cells were incubated with the terminal deoxynucleotidyl
transferase-mediated dUTP nick-end labeling (TUNEL) reaction mix
containing 10 U of terminal deoxyribosyltransferase, 10 mM dUTP-
biotin, and 2.5 mM cobalt chloride in 1× terminal transferase reaction
buffer (Boehringer Mannheim, Mannheim, Germany) for 1 hour at
37°C. The reaction was stopped by rinsing slides with PBS. Omission
of the terminal deoxyribosyltransferase enzyme was used as the nega-
tive control. The number of TUNEL-positive cells was counted in five
different fields, and representative fields were photographed. The ex-
periment was performed in duplicate and repeated three times.
Western Blot Analysis
Equal amounts (20 μg) of protein extracts from nonadherent cells
separated by 7.5% SDS-PAGE were transblotted to nitrocellulose,
blocked with 3% nonfat dry milk for 30 minutes at room tempera-
ture, and then incubated overnight with antibodies to phospho-Akt
Ser473, total Akt, phospho-p70S6K Thr389, total p70S6K, phospho-
ERK1/2 Thr202/Tyr204, total ERK1/2, phospho-c-Met Tyr1230/1234/1235
(Invitrogen), c-Met (Cell SignalingTechnologies, Austin,TX), Ras (C-20;
Santa Cruz Biotechnology), and β-actin (1:1000 dilution; Sigma) at 4°C.
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After washing in phosphate-buffered saline–Tween 20, themembranewas
incubated with appropriate horseradish peroxidase–conjugated secondary
antibodies (1:5000 dilution; Bio-Rad) for 1 hour. Protein bands were de-
tected by enhanced chemiluminescence (Amersham, Arlington Heights,
IL). The density of the bands was quantified by densitometric analysis
using an Image Tool System (Version 3.0; San Antonio, TX).
Reverse Transcription–PCR
Total RNA was extracted by the TRIzol reagent, and reverse tran-
scription was performed using the SuperScript II kit (Invitrogen) fol-
lowing the manufacturer’s instruction. Quantitative analysis of cDNA
amplification was assessed by incorporation of SYBRGreen (Bio-Rad)
into double-strand DNA. PCR primers for c-Met are as follows: for-
ward primer 5′-GGTGAAGTGTTAAAAGTTGGA-3′ and reverse
primer 5′-ATGAGGAGTGTGTACTCTTG-3′. Glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) expression (forward 5′-ATG-
TTCGTCATGGGTGTGAACCA-3′ and reverse 5′-TGGCAGG-
TTTTTCTAGACGGCAG-3′) was analyzed in the same run as
internal controls. The authenticity of the PCR products was verified
by melting curve analysis and gel electrophoresis. Relative messenger
RNA expression was determined by dividing the threshold of each
sample by the threshold of the internal control GAPDH. These
experiments were carried out in duplicate and repeated three times.
Statistical Analysis
Data were expressed as mean ± SD of three independent experi-
ments. Statistical analysis was done using one-way analysis of variance
followed by Tukey least significant difference t test for post hoc anal-
ysis. All tests of significance were set at P < .05.
Results
c-Met Overexpression Promotes Anoikis Resistance in Ovarian
Cancer Cells
PolyHEMA, due to its nonionic character, prevents cell attachment
to the substratum and matrix deposition, and thus keeps the cells in
suspension similar to single cells or multicellular aggregates isolated
from patients’ ascitic fluid [16]. Considering the status of c-Met over-
expression in malignant ovarian tumors and association with metas-
tasis, we determined whether HGF/c-Met signaling might provide
protection against apoptosis induced by a loss of matrix attachment.
To test it, we compared the sensitivity of three well-characterized hu-
man ovarian carcinoma cell lines CaOV-3, SKOV-3, andOVCAR-3 as
representative of the most common serous histologic subtypes of this
tumor to suspension-induced apoptosis: CaOV-3 and SKOV-3, which
express high levels of c-Met, and OVCAR-3, in which c-Met is almost
undetectable [9]. As shown in Figure 1, a loss of cell adhesion strongly
induced apoptosis in ovarian cancer cells as determined by Hoechst
and TUNEL staining. In contrast, significantly less apoptotic cells
were detected when CaOV-3 and SKOV-3 were treated with HGF,
whereas OVCAR-3 had virtually no effect (Figure 1). More than
21% of CaOV-3 and 11.5% SKOV-3 cells were dead 72 hours
after a loss of matrix contact, but only 10.5% of CaOV-3 and 4.5%
SKOV-3 cells treated with HGF were dead (Figure 1; P < .05). Con-
sistent with previous observations [18], HGF induced either little or
no apoptotic changes on monolayers (Figure 1).
Next, we sought to determine whether suppression of c-Met expres-
sion would abrogate the induction of anoikis. CaOV-3 and SKOV-3
were transfected with the c-Met-specific siRNA. Suppression of c-Met
expression (up to 90%) was confirmed byWestern blot analysis, which
detected active c-Met at 140 kDa, and real-time PCR (Figure 2A).
c-Met siRNA, but not nonspecific siRNA, significantly inhibited
HGF-mediated resistance to apoptosis of both cell lines in non-
adherent but not adherent cultures (Figure 2B). Similar results were
obtained with the specific c-Met inhibitor K252a (Figure 2B), which
inhibited tyrosine phosphorylation and thus the kinase activity of
c-Met (Figure 2C ) [19]. No inhibition was observed for siRNA or
K252a alone (Figure 2B). To investigate a possible direct cause effect
of increasing c-Met expression on cellular apoptotic response, we over-
expressed c-Met inOVCAR-3 and tested whether this was sufficient to
induce resistance to anoikis. Overexpression of c-Met was confirmed
by Western blot analysis (Figure 2D, inset). Consistent with our bio-
chemical data, c-Met–transfected OVCAR-3 cells showed an increased
resistance to apoptosis in response to HGF stimulation. There was no
effect in empty vector–transfected control cells (Figure 2D). These
results suggest a key role for c-Met to this resistance.
c-Met–Overexpressing Cells Show Increased Resistance to
Drug Treatment
One of the major modes of action of chemotherapeutic drugs is
through the induction of apoptosis. We therefore tested whether resis-
tance to anoikis may confer chemoresistance in ovarian cancer cells.
The role of c-Met expression in mediating chemoresistance in ovarian
cancer cells is of particular interest because current chemotherapeutic
agents have limited efficacy in patients with metastatic ovarian cancer
[2]. For these analyses, we focused on the effects of cisplatin and pac-
litaxel because these two agents are the first-line chemotherapeutic
drugs used in the treatment of ovarian cancer. Compared with mono-
layers, nonadherent cultures of both CaOV-3 and SKOV-3 cells were
consistently more resistant to cisplatin and paclitaxel at the clinically
relevant dose of 50 μM and 100 nM, respectively (Figure 3A) [20].
Moreover, nonadherent CaOV-3 and SKOV-3 showed increased resis-
tance to these drugs when cotreated in the presence of HGF (Fig-
ure 3A). Decreasing c-Met expression using c-Met siRNA in CaOV-3
and SKOV-3 cells enhanced their susceptibility to chemotherapy (Fig-
ure 3B). No inhibition was observed for siRNA alone (data not shown).
These results indicate that c-Met overexpression promotes ovarian can-
cer cell chemoresistance.
HGF Suppresses Anoikis through the PI3K/Akt and
ERK1/2 Pathways
We next wished to determine the molecular mechanisms by which
HGF/c-Met modulates the acquired survival. On binding of c-Met,
HGF activates several key signaling pathways including the PI3K/Akt
pathway. PI3K/Akt has been described as a central mediator of anti-
apoptotic signals [21]. For these studies, we used the specific PI3K
inhibitors. Treatment with 200 nM wortmannin (or another PI3K
inhibitor, LY294002; data not shown) caused a significant increase in
apoptosis as measured by Hoechst or TUNEL staining (Figure 4A).
These data suggest a role of the PI3K signaling pathway in this process.
The ERK1/2 mitogen-activated protein kinase (MAPK) has also
been associated with increased survival of cells and resistance to anoikis
in some systems [22,23]. To determine whether ERK1/2 activation
played a role inHGF-mediated inhibition of anoikis, we used a specific
MEK1/2 inhibitor, PD98059, to block the activation of ERK1/2. As
shown in Figure 4A, pretreatment with 50 μM PD98059 also signif-
icantly rendered CaOV-3 and SKOV-3 cells sensitive to anoikis despite
HGF stimulation (P < .05). Moreover, treatment with either inhibitor
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alone did not affect cellular apoptosis (data not shown). These results
suggest that HGF activates both PI3K and MAPK signaling pathways
to provide protection against anoikis. Similarly, CaOV-3 and SKOV-3
cells preincubated with wortmannin and PD98059 had little effect on
the apoptotic response of monolayers but consistently reduced the re-
sistance of nonadherent cells to cisplatin and paclitaxel than that of the
control cells (Figure 4B), demonstrating the essential role of these
signaling pathways also in chemoresistance.
HGF Stimulates Cross Talk Between the PI3K and MAPK
Signaling Pathways
To investigate any role of PI3K in regulating ERK1/2 activity, we
examined the effect of PI3K inhibitor on ERK1/2 phosphorylation
using phosphospecific antibodies in nonadherent CaOV-3 cells. As
shown in Figure 5A, strong phosphorylation of ERK1/2 was ob-
served after HGF stimulation. Preincubation of the cells with
PD98059 suppressed HGF-induced ERK1/2 phosphorylation
(Figure 5A). Interestingly, pretreatment with wortmannin or
LY294002 (data not shown) partially but significantly inhibited the
HGF-stimulated activating phosphorylation of ERK1/2 (Figure 5A).
These data suggest that PI3K, in addition to other factor(s), contrib-
utes to MAPK activity in response to HGF.
To elucidate the signaling pathway downstream of PI3K, we tested
the involvement of Akt using siRNA under nonadherent conditions.
The efficacy of silencing Akt was determined by immunoblot analysis
(Figure 5B). More importantly, reduced Akt expression with siRNA
significantly inhibited HGF-induced ERK1/2 activity compared with
cells transfected with nonspecific siRNA (Figure 5B), suggesting that
ERK1/2 activation is dependent on Akt. In addition, the simul-
taneous expression of Akt siRNA, but not nonspecific siRNA, sup-
pressed HGF-mediated resistance to apoptosis in nonadherent but
not adherent cells, confirming that the effect was Akt-specific
(Figure 5C ). The mTOR/p70S6K signaling pathway is another
PI3K effector, which is also involved in cell proliferation and growth
of several cell types. Although HGF stimulation induced p70S6K
phosphorylation in a PI3K-dependent manner, pretreatment of the
cells with rapamycin did not inhibit ERK1/2 activity (Figure 5A).
Treatment of cells with PD98059 or ERK1/2 siRNA showed no
effect on Akt kinase activity (Figure 5, A and B). Similar results
were also obtained with a different MEK1 inhibitor U0126 and
with a dominant-negative MEK1 (data not shown). Similar experi-
ments with SKOV-3 revealed changes in kinase activities indistin-
guishable from those in CaOV-3 (Figure W1). Together, these
results suggest that PI3K/Akt influences the MAPK pathway but
not vice versa.
Figure 1. HGF protected ovarian cancer cell from apoptosis induced by loss of cell adhesion. CaOV-3, SKOV-3, and OVCAR-3 cells were
plated on plastic Petri dishes (adherent) or polyHEMA-coated dishes (nonadherent) in the presence or absence of 10 ng/ml HGF for
72 hours. Representative results from Hoechst staining (nuclear morphology) and TUNEL labeling were shown. Bar, 50 μm. The number
of apoptotic cells were counted, and the bar diagram summarized the percentage of apoptotic cells from triplicate determination. Error
bars indicate the SD of the mean. *P < .05 versus untreated controls.
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Figure 2. Effects of c-Met silencing on anchorage-independent growth and anoikis resistance. CaOV-3 and SKOV-3 cells plated on cul-
ture dishes (adherent) or polyHEMA-coated dishes (nonadherent) were transfected with 10 nM nonspecific (NS) siRNA or c-Met siRNA
for 24 hours. (A) Equal amounts of protein (20 μg) were analyzed by Western blot using c-Met–specific antibodies. β-Actin was included
as a loading control. Right panel: Total RNA was isolated, and real-time PCR was performed with c-Met and GAPDH sequence-specific
primers. The amount of c-Met messenger RNA was normalized for the GAPDH present. (B) Cells were transfected with NS siRNA or
c-Met siRNA for 24 hours or pretreated with K252a inhibitor for 30 minutes and then treated with HGF (10 ng/ml) for 72 hours. Cell
apoptosis was determined with the TUNEL assay. (C) Twenty micrograms of protein was analyzed by Western blot using phospho
(p)-c-Met–specific antibodies. The same membranes were stripped and reprobed with antibodies to c-Met. β-Actin was included as a
loading control. (D) OVCAR-3 cells were transfected with empty vector (control) or human c-Met cDNA for 72 hours. Cells were analyzed
for c-Met expression by Western blot analysis (inset) or were subjected to TUNEL assay. The number of apoptotic cells was counted,
and the bar diagram summarized the percentage of apoptotic cells from triplicate determination. Error bars indicate the SD of the mean.
*P < .05 versus untreated controls.
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PI3K/Akt–Dependent ERK1/2 Activation Is Mediated by Ras
We next investigated the possible cross talk mechanism between
the PI3K/Akt and MAPK pathways. Although it is well known that
Ras plays a key role in growth factor–induced activation of MAPK,
it is also possible that ERK1/2 could be activated through Ras-
independent pathways [24]. To explore the role of Ras in the HGF-
induced activation of ERK1/2, we used Ras siRNA. Knocking down
Ras by siRNA in these nonadherent cells significantly inhibited HGF-
induced activating phosphorylation of ERK1/2, whereas nonspecific
siRNA had no effect (Figure 6A). Consistently, transfection with Ras
siRNA abolished HGF-mediated anoikis resistance and chemoresis-
tance in both cell lines (Figure 6B). The siRNA alone had no effect (data
not shown). In contrast, cells in monolayer cultures were sensitive to
cisplatin- and paclitaxel-induced apoptosis after transfection with Ras
siRNA (Figure 6B). Similar results were also obtained with a farnesyl-
transferase inhibitor FTI-277 used to inhibit Ras activity, confirming
that the effect was Ras-specific (data not shown).
Because MAPK activation requires PI3K as demonstrated in our
studies (Figure 5), we determined whether PI3K was involved in the
activation of MAPK through Ras. Because multiple studies implicate a
role for Ras in PI3K/Akt activation [25–27], we therefore examined
whether Ras was involved in Akt activation in response to HGF. As
shown in Figure 6A, treatment of CaOV-3 and SKOV-3 cells with
Ras siRNA was unable to block HGF-stimulated Akt activity, indicat-
ing that Ras does not regulate PI3K/Akt activation by HGF. Inter-
estingly, in contrast, the expression of a catalytically active mutant of
Akt (E17K) increased the activation of ERK1/2, which could be abol-
ished in the presence of the Ras siRNA (Figure 6C ). The nonspecific
Figure 3. HGF increased resistance of ovarian cancer cells to chemotherapeutic agents in nonadherent cultures. (A) CaOV-3 and SKOV-3
were plated on culture dishes (adherent) or polyHEMA-coated dishes (nonadherent) and subjected to 50 μM cisplatin (CDDP) or 100 nM
paclitaxel (PTX) treatment in the presence or absence of 10 ng/ml HGF for 72 hours. (B) To assess the specificity of c-Met, cells were
transfected with NS or c-Met siRNA before cisplatin, paclitaxel, or HGF treatment. Cell apoptosis was determined with the TUNEL assay.
The number of apoptotic cells was counted, and the bar diagram summarized the percentage of apoptotic cells from triplicate deter-
mination. Error bars indicate the SD of the mean. *P < .05 versus untreated controls.
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siRNA had no effect. Together, these results suggest that PI3K/Akt may
function upstream of Ras inHGF signaling leading toMAPK activation.
Discussion
A promising strategy to kill tumor cells is the induction of apoptosis
either alone or in synergy with chemotherapeutic drugs. Thus, un-
derstanding the molecular mechanisms of apoptotic resistance is of
paramount importance. In recent years, it is becoming clear that
the standard monolayer cultures do not fully reflect the pathological
properties seen in human tumors. This may be particularly relevant
to ovarian carcinomas, which exist as anchorage-independent single
cells or multicellular aggregates in the ascitic fluid of the peritoneal
cavity. In this study, by using three-dimensional suspension cultures,
we showed for the first time that c-Met overexpression endowed
ovarian carcinoma cells with an increased survival capacity that was
not apparent in the same cells grown as monolayers. Also, these cells
were more resistant to chemotherapy-induced apoptosis. Corre-
spondingly, down-regulating c-Met levels by siRNA led to increased
susceptibility to the chemotherapeutic agents. These examinations
would more closely approximate in vivo conditions. Thus, these find-
ings have important implications in killing ascitic ovarian carcinoma
cells during chemotherapy.
Although it is generally thought that tumor or oncogene-transformed
cells are anchorage-independent and therefore can proliferate even
under loss of matrix adhesion [28], many human ovarian cancer cell
lines underwent apoptosis when deprived of matrix attachment in
cell culture. These results suggest that paracrine/autocrine growth
factors produced by stromal and/or tumor cells in the tumor micro-
environment may be important for cancer cell survival and progres-
sion. Our results suggest that HGF may be such a factor for ovarian
cancer cells. In vivo, HGF is found at high levels in malignant ovar-
ian cystic (4.1-16.0 ng/ml) and ascitic fluid (2.3-11.2 ng/ml) from
women with ovarian carcinomas [10]. This is consistent with the
concentration of HGF used in our experiments (10 ng/ml). The ex-
pression of HGF is primarily produced by immune cells and stromal
fibroblasts. We have shown that ovarian cancer cells may also synthe-
size small amounts of HGF [29]. The fact that most (70%) ovarian
Figure 4. Signaling pathways for HGF-induced anoikis resistance and chemoresistance. (A) CaOV-3 and SKOV-3 cells plated on culture
dishes (adherent) or polyHEMA-coated dishes (nonadherent) were pretreated with 200 nM wortmannin (Wt) or 50 μM PD98059 (PD) for
30 minutes and (B) subjected to 50 μM cisplatin (CDDP) or 100 nM paclitaxel (PTX) treatment in the presence or absence of 10 ng/ml
HGF for 72 hours. Cell apoptosis was determined with the TUNEL assay. The number of apoptotic cells was counted, and the
bar diagram summarized the percentage of apoptotic cells from triplicate determination. Error bars indicate the SD of the mean.
*P < .05 versus untreated controls.
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Figure 5. Cross talk between PI3K and ERK1/2 in response to HGF. (A) CaOV-3 cells plated on polyHEMA-coated dishes were pretreated
with 50 μM PD98059 (PD), 200 nM wortmannin (Wt), or 20 nM rapamycin (Rp) for 30 minutes or (B) transfected with nonspecific (NS),
ERK1/2 or Akt siRNA for 24 hours and then treated with HGF (10 ng/ml) for 15 minutes. Equal amounts of protein (20 μg) were analyzed
by Western blot using specific antibodies recognizing phospho (p)-Akt, p-p70S6K, or p-ERK1/2. The same membranes were stripped and
reprobed with antibodies to total Akt, p70S6K, and ERK1/2. β-Actin was also included as a loading control. The signal intensity was
determined by densitometry and expressed as p-Akt, p-p70S6K, and p-ERK1/2 relative to total Akt, p70S6K, ERK1/2, and β-actin for each
sample. (C) Cell apoptosis was determined with the TUNEL assay. The number of apoptotic cells was counted, and the bar diagram
summarized the percentage of apoptotic cells from triplicate determination. Error bars indicate the SD of the mean. *P < .05 versus
untreated controls.
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Figure 6. PI3K functions upstream of Ras in response to HGF. CaOV-3 and SKOV-3 cells were transfected with non-specific (NS) siRNA
or Ras siRNA for 24 hours and then treated with HGF (10 ng/ml) for 15 minutes. (A) Ras expression was determined by Western blot. Akt
and ERK1/2 activities were analyzed using anti–phospho-specific (p-) Akt and p-ERK1/2 antibodies. (B) CaOV-3 and SKOV-3 cells plated
on culture dishes (adherent) or polyHEMA-coated dishes (nonadherent) were transfected with NS siRNA or Ras siRNA for 24 hours and
then subjected to 50 μM cisplatin (CDDP) or 100 nM paclitaxel (PTX) for 72 hours in the presence or absence of 10 ng/ml HGF. Cell
apoptosis was determined with the TUNEL assay. The number of apoptotic cells was counted, and the bar diagram summarized the
percentage of apoptotic cells from triplicate determination. (C) CaOV-3 and SKOV-3 cells were cotransfected with a constitutively active
Akt (E17K) and NS siRNA or Ras siRNA for 24 hours. Ras expression was determined by Western blot. Akt and ERK1/2 activities were
analyzed using anti–p-Akt and p-ERK1/2 antibodies. β-Actin was also included as a loading control. The signal intensity was determined
by densitometry and expressed as p-Akt and p-ERK1/2 relative to total Akt and ERK1/2 for each sample. Error bar indicates the SD of the
mean. *P < .05 versus untreated controls.
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carcinomas express c-Met and these are overexpressed in ∼30% cases
suggests that our findings are relevant to a large number of ovarian
carcinomas [3,4,6]. Given its apparent role in oncogenic signals, tar-
geted therapies that inhibit the function of HGF or c-Met alone or in
combination with other receptor tyrosine kinases may lead to signifi-
cant tumor inhibition [30]. In comparison to monolayer cultures, the
effect of HGF/c-Met on survival became evident only in the three-
dimensional setting. This may represent a redirection of signals by dis-
tinct signaling pathways or coupled to other pathways on a transition
from two-dimensional to three-dimensional cultures [31–33].
Our results showing inhibition of MAPK phosphorylation by
wortmannin and LY294002 demonstrate that HGF-stimulated
MAPK is PI3K-dependent. This positive regulatory effect of PI3K
on MAPK activity resulted in anoikis resistance. Conversely, inhibi-
tion of MEK1 did not affect Akt phosphorylation or activity, suggest-
ing that PI3K influences the MAPK pathway but not vice versa. These
data demonstrate for the first time the presence of a direct relation
between PI3K and MAPK in HGF-mediated signal transduction.
One PI3K effector is Akt [21]. In contrast to the observation that
growth factors, such as epidermal growth factor and insulin-like growth
factor-1, do not stimulate PI3K-mediated ERK1/2 activity in a Akt-
dependent manner [34,35], we found that Akt was essential for HGF-
induced stimulation of ERK1/2 and this regulation is important for the
suppression of anoikis in ovarian cancer cells. Unlike Akt, involvement of
ERK1/2 in the HGF-mediated antiapoptotic function is variable. For
example, it has been previously reported that HGF-induced ERK1/2
activation inhibited the apoptosis induced by serum starvation and
UV irradiation [36]. In contrast, the presence of ERK1/2–independent
antiapoptotic effects of HGF has also been demonstrated [37].
Whereas PI3K/Akt and MAPK are two parallel pathways in some
cell types, we found that they were related pathways. In addressing the
cross talk mechanism between these two pathways, we examined the
role of Ras. Interestingly, despite striking evidence that Ras binds to
and activates PI3K [25–27], we found that blocking Ras had no effect
on HGF-stimulated PI3K activation. In contrast, our results suggest a
role for PI3K/Akt upstream of Ras. The ectopic expression of a consti-
tutively active form of Akt stimulated ERK1/2 activities. This activation
was completely blocked by the down-regulation of Ras with siRNA.Un-
like other growth factor receptors, such as epidermal growth factor re-
ceptor, there is evidence that c-Met can directly associate with and
activate PI3K; perhaps it may explain why PI3K is not subjected to reg-
ulation by Ras in our studies [38]. Consistent with our results, it has
been reported that PI3K is able to stimulate Ras at least in certain sys-
tems, suggesting the importance of cell context and stimuli [39–41].
Aberrant Ras activation and signaling are commonly seen in ovarian
cancer. The expression of oncogenic RasV12 has been shown to abro-
gate anoikis in vitro and is tumorigenic in nude mice [42,43].
In summary, using a three-dimensional suspension culture condi-
tion, we have discovered a role for c-Met in survival that could pro-
vide a therapeutic rationale for the use of c-Met inhibitors to prevent
ascitic dissemination and to resensitize ovarian tumor cells to stan-
dard chemotherapy.
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Figure W1. Cross talk between PI3K and ERK1/2 in response to HGF in SKOV-3 cells. (A) Cells plated on polyHEMA-coated dishes were
pretreated with 50 μM PD98059 (PD), 200 nM wortmannin (Wt), or 20 nM rapamycin (Rp) for 30 minutes or (B) transfected with non-
specific (NS), ERK1/2, or Akt siRNA for 24 hours and then treated with HGF (10 ng/ml) for 15 minutes. Equal amounts of protein (20 μg)
were analyzed by Western blot using specific antibodies recognizing phospho (p)-Akt, p-p70S6K, or p-ERK1/2. The same membranes
were stripped and reprobed with antibodies to total Akt, p70S6K, and ERK1/2. β-Actin was also included as a loading control. The signal
intensity was determined by densitometry and expressed as p-Akt, p-p70S6K, and p-ERK1/2 relative to total Akt, p70S6K, ERK1/2, and
β-actin for each sample. (C) Cell apoptosis was determined with the TUNEL assay. The number of apoptotic cells was counted, and
the bar diagram summarized the percentage of apoptotic cells from triplicate determination. Error bars indicate the SD of the mean.
*P < .05 versus untreated controls.
